The FDA approved aminolevulinic acid hydrochloride 10% (Ameluz) in combination with photodynamic therapy for treating adults with superficial basal cell carcinoma, according to an announcement by manufacturer Biofrontera. Basal cell carcinoma is the most common form of skin cancer.
This approval provides a new treatment option for the most prevalent form of skin cancer in adults.
No published comments yet.
The chart totals every SEC-reported transaction by month and share count, separating informative purchases and sales from non-informative awards, vesting, exercises, tax withholding and transfers. Records without a reported price remain included. Only informative purchases and sales affect the conservative sentiment signal.
Recent SEC-reported share and derivative transactions in Biofrontera Inc..
0 discretionary purchases · 0 discretionary sales
Confidence: Low
| Insiders | Activity | Description | Shares | Avg. price / share | Est. value | Trade date |
|---|---|---|---|---|---|---|
| CEO & ChairmanLuebbert Hermann | Non-informative buy | Common StockExercise or conversion; not an open-market trade (M) | 62,500 | — | — | Jul 28, 2026 |
| Chief Financial OfficerLeffler Eugene Frederick | Non-informative buy | Exercise or conversion; not an open-market trade |
| Insiders | Activity | Description | Shares | Avg. price / share | Est. value | Trade date |
|---|---|---|---|---|---|---|
| CEO & ChairmanLuebbert Hermann | Non-informative buy | Restricted Stock UnitsCompany grant or award (A) | 125,000 | — | — | Mar 4, 2026 |
| CEO & ChairmanLuebbert Hermann | Non-informative buy |
As filed with the SEC. Estimated value is shown only for purchases or sales with a positive reported transaction price; awards, gifts and similar activity are not assigned an assumed market value. Amendments may change the record. This is not investment advice.
Quarterly reported positions. These filings can arrive up to 45 days after quarter-end and are not real-time trades.
Institutional ownership: 19.36%
Open short positions reported twice monthly; this is not daily short-sale volume.
Recent reported earnings per share compared with the analyst consensus available from Nasdaq.
| 31,250 |
| — |
| — |
| Jul 28, 2026 |
| CEO & ChairmanLuebbert Hermann | Non-informative buy | Common StockExercise or conversion; not an open-market trade (M) | 137,500 | — | — | Mar 5, 2026 |
| Chief Financial OfficerLeffler Eugene Frederick | Non-informative buy | Common StockExercise or conversion; not an open-market trade (M) | 87,500 | — | — | Mar 5, 2026 |
| DirectorWeber Kevin Daniel | Non-informative buy | Employee stock option (right to buy)Company grant or award (A) | 20,000 | — | — | Mar 4, 2026 |
| Employee stock option (right to buy)Company grant or award (A) |
| 125,000 |
| — |
| — |
| Mar 4, 2026 |
| Chief Financial OfficerLeffler Eugene Frederick | Non-informative buy | Restricted Stock UnitsCompany grant or award (A) | 62,500 | — | — | Mar 4, 2026 |
| Chief Financial OfficerLeffler Eugene Frederick | Non-informative buy | Employee stock option (right to buy)Company grant or award (A) | 62,500 | — | — | Mar 4, 2026 |
| DirectorLanckriet Heikki | Non-informative buy | Employee stock option (right to buy)Company grant or award (A) | 20,000 | — | — | Mar 4, 2026 |
| DirectorHoffman Beth J. | Non-informative buy | Employee stock option (right to buy)Company grant or award (A) | 20,000 | — | — | Mar 4, 2026 |
| Chief Commercial OfficerJones George Patrick | Non-informative buy | Restricted Stock UnitsCompany grant or award (A) | 50,000 | — | — | Mar 4, 2026 |
| Chief Commercial OfficerJones George Patrick | Non-informative buy | Employee stock option (right to buy)Company grant or award (A) | 50,000 | — | — | Mar 4, 2026 |
| DirectorBORER JOHN J III | Non-informative buy | Employee stock option (right to buy)Company grant or award (A) | 20,000 | — | — | Mar 4, 2026 |
| DirectorBiofrontera AG | Non-informative buy | Series D Convertible Preferred StockOpen-market or private transaction (P) | 4,831,172 | — | — | Sep 16, 2025 |
| Chief Commercial OfficerJones George Patrick | Non-informative buy | Employee stock option (right to buy)Company grant or award (A) | 100,000 | — | — | Sep 15, 2025 |
| CEO & ChairmanLuebbert Hermann | Non-informative buy | Common StockExercise or conversion; not an open-market trade (M) | 137,500 | — | — | Sep 10, 2025 |
| Chief Financial OfficerLeffler Eugene Frederick | Non-informative buy | Common StockExercise or conversion; not an open-market trade (M) | 87,500 | — | — | Sep 10, 2025 |
| DirectorWeber Kevin Daniel | Non-informative buy | Employee stock option (right to buy)Company grant or award (A) | 20,000 | — | — | Jul 22, 2025 |
| CEO & ChairmanLuebbert Hermann | Non-informative buy | Restricted Stock UnitsCompany grant or award (A) | 125,000 | — | — | Jul 22, 2025 |
| CEO & ChairmanLuebbert Hermann | Non-informative buy | Employee stock option (right to buy)Company grant or award (A) | 125,000 | — | — | Jul 22, 2025 |
| Chief Financial OfficerLeffler Eugene Frederick | Non-informative buy | Restricted Stock UnitsCompany grant or award (A) | 62,500 | — | — | Jul 22, 2025 |
| Chief Financial OfficerLeffler Eugene Frederick | Non-informative buy | Employee stock option (right to buy)Company grant or award (A) | 62,500 | — | — | Jul 22, 2025 |
| DirectorLanckriet Heikki | Non-informative buy | Employee stock option (right to buy)Company grant or award (A) | 20,000 | — | — | Jul 22, 2025 |
| DirectorHoffman Beth J. | Non-informative buy | Employee stock option (right to buy)Company grant or award (A) | 20,000 | — | — | Jul 22, 2025 |
| DirectorBORER JOHN J III | Non-informative buy | Employee stock option (right to buy)Company grant or award (A) | 20,000 | — | — | Jul 22, 2025 |
| Owner | Activity | Change | Shares held | Value (thousands) | Reported |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | Buy | 111,647 (9.592%) | 1,275,609 | $1,977 | 6/30/2026 |
| Aigh Capital Management Llc | Sell | -175,300 (-19.154%) | 739,910 | $1,147 | 6/30/2026 |
| Renaissance Technologies Llc | Buy | 157,505 (New) | 157,505 | $244 | 6/30/2026 |
| Vanguard Group Inc | Unchanged | 0 (0%) | 113,951 | $177 | 12/31/2025 |
| Citadel Advisors Llc | Buy | 104,941 (New) | 104,941 | $163 | 6/30/2026 |
| Jane Street Group, Llc | Buy | 93,000 (New) | 93,000 | $144 | 6/30/2026 |
| Geode Capital Management, Llc | Sell | -32,611 (-29.836%) | 76,689 | $119 | 6/30/2026 |
| Vanguard Capital Management Llc | Buy | 19,126 (36.602%) | 71,380 | $111 | 6/30/2026 |
| Vanguard Fiduciary Trust Co | Unchanged | 0 (0%) | 61,697 | $96 | 6/30/2026 |
| Xtx Topco Ltd | Buy | 29,401 (130.712%) | 51,894 | $80 | 6/30/2026 |
| Hrt Financial Lp | Buy | 43,349 (New) | 43,349 | $67 | 6/30/2026 |
| Northern Trust Corp | Buy | 31,536 (New) | 31,536 | $49 | 6/30/2026 |
Source: Nasdaq
| Settlement date | Short interest | Avg. daily volume | Change vs. previous report | Days to cover |
|---|---|---|---|---|
| Aug 31, 2026 | 255,272 | 674,900 | +675.74% | 1.00 |
| Aug 14, 2026 | 32,907 | 464,283 | -46.12% | 1.00 |
| Jul 31, 2026 | 61,079 | 359,826 | +152.84% | 1.00 |
| Jul 15, 2026 | 24,157 | 437,640 | -13.38% | 1.00 |
| Jun 30, 2026 | 27,890 | 314,176 | -50.25% | 1.00 |
| Jun 15, 2026 | 56,055 | 203,235 | -19.15% | 1.00 |
| May 29, 2026 | 69,336 | 130,648 | -17.84% | 1.00 |
| May 15, 2026 | 84,396 | 354,759 | — | 1.00 |
Source: Nasdaq
| Fiscal quarter | Reported | EPS | Consensus | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 13, 2026 | -0.05 | -0.17 | +70.59% |
| Mar 2026 | May 14, 2026 | -0.41 | -0.18 | -127.78% |
| Dec 2025 | Mar 19, 2026 | 0.50 | 0.29 | +72.41% |
| Sep 2025 | Nov 12, 2025 | -0.59 | -0.6 | +1.67% |
Source: Nasdaq
